These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23299707)

  • 21. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab: new horizons in the treatment of osteoporosis.
    Wilton JM
    Nurs Womens Health; 2011; 15(3):249-52. PubMed ID: 21672176
    [No Abstract]   [Full Text] [Related]  

  • 24. Denosumab: recent update in postmenopausal osteoporosis.
    Silva I; Branco JC
    Acta Reumatol Port; 2012; 37(4):302-13. PubMed ID: 24126422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
    Capozzi A; Lello S; Pontecorvi A
    Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab: a novel antiresorptive drug for osteoporosis.
    Suresh E; Abrahamsen B
    Cleve Clin J Med; 2015 Feb; 82(2):105-14. PubMed ID: 25897599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab, osteoporosis, and prevention of fractures.
    Blythe SL
    N Engl J Med; 2009 Nov; 361(22):2189-90; author reply 2190-1. PubMed ID: 19950410
    [No Abstract]   [Full Text] [Related]  

  • 32. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
    Sutton EE; Riche DM
    Ann Pharmacother; 2012; 46(7-8):1000-9. PubMed ID: 22837347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab, osteoporosis, and prevention of fractures.
    Blackwood J
    N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950411
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Data from extension trials: denosumab and zoledronic acid.
    Dore RK
    Curr Osteoporos Rep; 2012 Mar; 10(1):16-21. PubMed ID: 22086442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Denosumab for postmenopausal osteoporosis?
    Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
    Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.
    Harris KB; Nealy KL; Jackson DJ; Thornton PL
    J Pharm Pract; 2012 Jun; 25(3):310-8. PubMed ID: 22550161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.